INDEPENDENT RESEARCH MONITOR
Selected work with a defined mechanism or credible development path. No clinical benefit is implied.
Selected work with a defined mechanism or credible development path. No clinical benefit is implied.
No records match these filters.
Translational / Phase 1 preparation
Transdermal low-dose theophylline • HDAC2 activation
ForTra-funded GMP/patch optimisation • Phase 1 in healthy volunteers planned
Evidence level: No human MS efficacy data • preclinical mechanism + formulation development
Next substantive checkpoint: Optimised patch validation, GMP manufacture and first-in-human safety/PK; public trial registration
Preclinical / clinical-development candidate
Histamine H3 receptor antagonist
Peer-reviewed multi-model validation • no registered MS trial
Evidence level: Human oligodendroglia assays + mouse models • no patient efficacy data
Next substantive checkpoint: Drug-development/formulation work and formal clinical-trial registration
Preclinical / translational
DITPA • MCT8-independent thyroid-hormone analogue
Active Monash programme through 2028 • NeuOrphan describes it as preclinical
Evidence level: Preclinical only • no proven clinical benefit in MS
Next substantive checkpoint: Peer-reviewed confirmation, regulatory package and public registration of an MS human trial
Lead optimisation
Small-molecule OPC differentiation lead
Peer-reviewed preclinical efficacy in human OPCs in vitro and mouse demyelination
Evidence level: Preclinical only • no proven clinical benefit in MS
Next substantive checkpoint: Medicinal-chemistry optimisation, PK/toxicology and selection of a clinical candidate
Development candidate / preclinical
Fixed-dose binary small-molecule combination
Candidate selected from synergistic remyelination-inducing drug combinations
Evidence level: Preclinical only • no proven clinical benefit in MS
Next substantive checkpoint: Pre-IND development and formal clinical-trial registration
Preclinical / licensing
Novel small-molecule mGluR5 agonists
Human oligodendrocyte activity + animal-model remyelination; patent pending
Evidence level: Preclinical only • no proven clinical benefit in MS
Next substantive checkpoint: Lead selection, drug-development optimisation and IND-enabling work
Preclinical cell therapy
Directly induced neural stem-cell transplantation
Peer-reviewed proof-of-concept in chronic demyelination models
Evidence level: Preclinical only • no proven clinical benefit in MS
Next substantive checkpoint: Delivery, dosing and safety work needed before MS clinical translation
Preclinical cell therapy
Engineered human oligodendrocyte progenitor cells
Enhanced migration and remyelination in rodent chronic-lesion models
Evidence level: Preclinical only • no proven clinical benefit in MS
Next substantive checkpoint: Manufacturing, long-term safety and translational studies before human testing